NCT06381453View on ClinicalTrials.gov

Belimumab in Autoimmune Hepatitis

PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 11, 2024

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2029

Conditions
Autoimmune Hepatitis
Interventions
DRUG

Belimumab Auto-Injector [Benlysta]

Belimumab 200 MG/ML \[Benlysta\] will be given once a week as single-dose autoinjector

Trial Locations (1)

M5G 2C4

RECRUITING

Toronto General Hospital, Toronto

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University Health Network, Toronto

OTHER